.Nature Medication, Released online: 03 September 2024 doi:10.1038/ s41591-024-03223-zThis Viewpoint asks for inclusion of people with MASLD as well as measurement of liver outcomes in cardio-- renal-- metabolic tests, when information propose mechanistically possible advantages as well as scientific safety and security-- and outlines factors for trial layout and regulative commendation.